These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27690665)

  • 1. Chemical JAK inhibitors for the treatment of rheumatoid arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    Expert Opin Pharmacother; 2016 Nov; 17(16):2215-2225. PubMed ID: 27690665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
    Iwata S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K; Tanaka Y
    Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib for the treatment of rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Sep; 12(9):911-9. PubMed ID: 27427830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of baricitinib in the treatment of rheumatoid arthritis.
    Richez C; Truchetet ME; Kostine M; Schaeverbeke T; Bannwarth B
    Expert Opin Pharmacother; 2017 Sep; 18(13):1399-1407. PubMed ID: 28737053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
    Tanaka Y
    J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
    Bannwarth B; Kostine M; Poursac N
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
    [No Abstract]   [Full Text] [Related]  

  • 11. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
    Mogul A; Corsi K; McAuliffe L
    Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis.
    Lundquist LM; Cole SW; Sikes ML
    World J Orthop; 2014 Sep; 5(4):504-11. PubMed ID: 25232526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK inhibitors for rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.
    Vaddi K; Luchi M
    Expert Opin Investig Drugs; 2012 Jul; 21(7):961-73. PubMed ID: 22612502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis.
    Cutolo M; Meroni M
    J Inflamm Res; 2013 Nov; 6():129-37. PubMed ID: 24453498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.
    Moura RA; Fonseca JE
    Front Med (Lausanne); 2020; 7():607725. PubMed ID: 33614673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
    Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
    Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.
    Cutolo M
    Ther Adv Musculoskelet Dis; 2013 Feb; 5(1):3-11. PubMed ID: 23515130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibitors: A broadening approach in rheumatoid arthritis.
    Lam S
    Drugs Today (Barc); 2016 Aug; 52(8):467-469. PubMed ID: 27722215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.